THDBH-150 is under clinical development by Tonghua Dongbao Pharmaceutical and currently in Phase I for Hyperuricemia. According to GlobalData, Phase I drugs for Hyperuricemia have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how THDBH-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

THDBH-150 overview

THDBH-150 is under development for the treatment of gouty arthritis (gout) and hyperuricemia. The therapeutic candidate is a dual target inhibitor acts by targeting xanthine oxidase (XO) and urate transporter 1 (URAT1).

Tonghua Dongbao Pharmaceutical overview

Tonghua Dongbao Pharmaceutical (Tonghua Dongbao) is a manufacturer supplier of pharmaceutical products. It offers chinese and western medicines, biological medicine, and medical instruments including insulin glargine injection, human insulin injection, zhennaoning capsule, compound methionine choline tablets, pediatric paracetamol huang namin granules, needle for injection pen and pen type insulin syringe. The company also provides chronic disease management platform. It markets pharmaceutical products under the brands of Dongbao, Pingshulin, Ruishulin and Gan Shulin. The company markets its products through a network of distribution partners and medical stores in China. Tonghua Dongbao is headquartered in Tonghua, Jilin, China.

For a complete picture of THDBH-150’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.